Mylan, which says it makes about one of every 11 drugs prescribed to Americans, has said it wants to stay independent and that a combination with Teva would face antitrust hurdles. The deal would create a generics powerhouse with more than US$27 billion in revenue and re-establish Teva as the unchallenged giant in the industry. The Israeli company has lost market share to Indian manufacturers such as Sun Pharmaceutical Industries Ltd. Chief Executive Officer Erez Vigodman has pledged to look for deals as Teva's best-selling product, a branded treatment for multiple sclerosis called Copaxone, faces potential competition from generics. "The attraction for Teva is that this deal would immediately allow them to grow and reduce their exposure to the impending drop in Copaxone sales," said Sam Fazeli, an analyst at Bloomberg Intelligence in London. "We still would have to consider the ramifications of antitrust regulation." A Teva purchase of Mylan faces obstacles.